, /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: ), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCsTM), today announced it is partnering with the FSHD Society and joining the global community of patients, caregivers, and healthcare providers to raise awareness of facioscapulohumeral muscular dystrophy in support of World FSHD Day. The FSHD Society is hosting a webinar with Avidity today at to share recent unprecedented , a rare, hereditary disorder marked by life-long, relentless loss of muscle function, significant pain, fatigue, and progressive disability.
"This World FSHD Day, we are excited to be joining the FSHD Society to share recent unprecedented data from our FORTITUDE study with the patient and caregiver community," said , president and chief executive officer at Avidity. "We know the FSHD community is eagerly waiting for an approved therapy and we are committed to bringing forward a treatment as quickly as possible to the many families worldwide who are affected by FSHD. We are extremely thankful for the important contributions of patients, caregivers and families that continue to better inform our ongoing research and development as we advance for people living with FSHD.
" "As the world's largest research-focused patient organization, we are dedicated to speeding the delivery of treatments and a cure for FSHD. With the remarkable data from Avidity's FORTITUDE study presented l.
